19:34 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

BioLineRx reports response, survival data for BL-8040, Keytruda combo in pancreatic cancer

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the Phase IIa COMBAT/KEYNOTE-202 trial showing that BL-8040 plus Keytruda pembrolizumab led to a disease control rate (DCR) of 34.5%, including one partial response and nine cases...
16:18 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Priority Review for Immunomedics' ADC for TNBC

FDA accepted and granted Priority Review to a BLA from Immunomedics Inc. (NASDAQ:IMMU) seeking accelerated approval of sacituzumab govitecan (IMMU-132) to treat metastatic triple-negative breast cancer (TNBC) in a third-line setting. Its PDUFA date is...
19:28 , Jul 18, 2018 |  BC Extra  |  Company News

Priority Review for Immunomedics' ADC for TNBC

FDA accepted and granted Priority Review to a BLA from Immunomedics Inc. (NASDAQ:IMMU) seeking accelerated approval of sacituzumab govitecan (IMMU-132) to treat metastatic triple-negative breast cancer in a third-line setting. Its PDUFA date is Jan....
19:53 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Opdivo plus Yervoy approved for mCRC

Bristol-Myers Squibb Co. (NYSE:BMY) said FDA granted accelerated approval to Opdivo nivolumab plus Yervoy ipilimumab to treat patients 12 years and older with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer...
19:14 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Array reports Phase III OS data for encorafenib/binimetinib/Erbitux triple combo in mCRC

Array BioPharma Inc. (NASDAQ:ARRY) reported additional data from the safety lead-in portion of the open-label, international Phase III BEACON CRC trial showing that encorafenib (LGX818) plus binimetinib (MEK162) and Erbitux cetuximab led to a one-year...
19:31 , Jun 15, 2018 |  BC Week In Review  |  Financial News

Immunomedics raises $276M on heels of BLA submission

Immunomedics Inc. (NASDAQ:IMMU) raised on June 13 $276 million through the sale of 11.5 million shares at $24 in a follow-on underwritten by Morgan Stanley, Cowen, Jefferies and Wells Fargo Securities. The offering price is...
17:11 , Jun 13, 2018 |  BC Extra  |  Financial News

Immunomedics raises $276M on heels of BLA submission

Immunomedics Inc. (NASDAQ:IMMU) raised $276 million through the sale of 11.5 million shares at $24 in a follow-on underwritten by Morgan Stanley, Cowen, Jefferies and Wells Fargo Securities. The offering price is just above Immunomedics'...
14:11 , May 18, 2018 |  BC Week In Review  |  Clinical News

Immunomedics reports Phase I/II metastatic breast cancer data for sacituzumab govitecan

Immunomedics Inc. (NASDAQ:IMMU) said sacituzumab govitecan (IMMU-132) led to an overall response rate (ORR) of 31% in a cohort of 54 patients with estrogen receptor-positive, HER2-negative metastatic breast cancer in the Phase I/II IMMU-132-01 trial....
20:46 , May 17, 2018 |  BC Extra  |  Clinical News

Immunomedics reports Phase I/II metastatic breast cancer data

Immunomedics Inc. (NASDAQ:IMMU) said sacituzumab govitecan (IMMU-132) led to an overall response rate (ORR) of 31% in a cohort of 54 patients with estrogen receptor-positive, HER2-negative metastatic breast cancer in the Phase I/II IMMU-132-01 trial....
22:55 , May 11, 2018 |  BioCentury  |  Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May...